Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
clesrovimab-cfor
- Development stage
- Approved
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intramuscular
01
Overview
Clesrovimab-cfor is a fully human monoclonal antibody that targets the prefusion F protein of respiratory syncytial virus (RSV). It binds with high affinity to site IV of the RSV F protein, preventing viral fusion and entry into host cells. This mechanism provides direct protection against RSV infection. Clesrovimab-cfor is highly potent in vitro (approximately 50-fold more than palivizumab) and is equipotent against both RSV-A and RSV-B strains. The drug features YTE substitutions for extended half-life (~44 days), allowing for single-dose administration regardless of infant weight. It achieves high nasal tissue distribution at sites of infection and has demonstrated robust efficacy in reducing medically attended lower respiratory infections (MALRI) and hospitalizations due to RSV in infants during their first season. Clesrovimab-cfor was developed by Merck Sharp & Dohme (Merck) and is marketed under the brand name Enflonsia[1][3][4][5][6][7][8][9].
- Brand names
- Enflonsia
- Other names
- Anti RSV F antibody - Merck Sharp & Dohme
02
Targets
RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on clesrovimab-cfor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on clesrovimab-cfor.